LEP and Hepatic steatosis: Both elafin delivery approaches also significantly increased circulating leptin levels (Fig. 6C) and significantly reduced circulating IFNγ levels, food consumption, fat mass gain, fasting blood glucose levels, and liver steatosis of the HFD-treated male mice (Fig. 6D–H and S6F).